BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 31, 2010
View Archived Issues
AF-792, a selective inhibitor of P2X2/3 and P2X3 receptors, regulates bladder activity in rats
Read More
Escitalopram prevents relapse in patients with alcoholism and comorbid affective disorders
Read More
AstraZeneca reviews Q2 progress
Read More
Temsirolimus reduces hypersensitivity in mice with spare nerve injury-induced neuropathic pain
Read More
Novel xanthine dehydrogenase/oxidase inhibitors show potent hypouricemic effects in vivo
Read More
Representative of new class of SGLT2 inhibitors enters phase II development
Read More
Genentech describes selection of novel Chk1 inhibitor for further development
Read More
Shionogi and LifeCycle end North American license agreement for Fenoglide
Read More
Bioniche and University of Ottawa sign agreement for antianxiety compounds
Read More
Chroma Therapeutics advances CHR-5154 into preclinical development
Read More
FDA extends review of eribulin NDA for advanced or metastatic breast cancer
Read More
Shelf life reduced for Panvax Junior influenza vaccine
Read More
Novel PI3K inhibitors claimed by Cellzome
Read More
Patient recruitment begins for phase II MK-2206 trial in colorectal cancer
Read More
Otsuka identifies new adenosine A2A receptor agonists
Read More
Novel antagonists of MCHR-1 presented by sanofi-aventis
Read More
Novel FAAH1 inhibitors disclosed by sanofi-aventis
Read More
Trius initiates phase III program of torezolid phosphate
Read More
FDA extends PDUFA goal date for ezogabine
Read More
FDA approves Bionovo's CMC plan for Menerba
Read More
FDA issues complete response letter on motavizumab
Read More
FDA grants priority review for Iluvien in DME
Read More
Kythera and Intendis to develop ATX-101 outside North America
Read More
Achaogen awarded contract to develop ACHN-490 and other antibiotics
Read More
FDA approves additional strengths of Medicis's Solodyn for acne vulgaris
Read More